Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 92
- Registration Number
- NCT05956899
- Locations
- 🇲🇾
University Malaya, Pantai Valley, Kuala Lumpur, Malaysia
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 1028
- Registration Number
- NCT05841849
- Locations
- 🇨🇳
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT04912271
Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04585412
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 29
- Registration Number
- NCT04308837
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mount Sinai St. Luke's, New York, New York, United States
🇺🇸Mount Sinai West, New York, New York, United States
Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Universidade Federal Fluminense
- Target Recruit Count
- 80
- Registration Number
- NCT04060771
- Locations
- 🇧🇷
Hospital Universitário Antonio Pedro, Niterói, Rio De Janeiro, Brazil
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Costantine Albany
- Registration Number
- NCT03960151
Cisplatin Disposition and Kidney Injury
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT03817970
- Locations
- 🇺🇸
UCHealth-Metro Denver, Denver, Colorado, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 248
- Registration Number
- NCT03674294
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 560
- Registration Number
- NCT03606369
- Locations
- 🇲🇽
Instituto Nacional de Cancerología, Mexico City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.